Focuses on developing treatments for pain and other serious conditions using its proprietary Chromovert technology.
Chromocell Therapeutics Corporation, a clinical-stage biotechnology company headquartered in Freehold, New Jersey, is dedicated to advancing the development and commercialization of innovative therapeutics aimed at alleviating pain. Central to its mission is the selective targeting of the sodium ion-channel NaV1.7, alongside other receptors within the NaV family, known for their role in pain signaling.
At the forefront of Chromocell Therapeutics' pipeline is CC8464, its lead compound currently undergoing Phase 2a clinical trials. This novel therapeutic is being investigated for its potential in treating erythromelalgia a condition characterized by severe burning pain in the extremities as well as other forms of neuropathic pain and acute and chronic eye pain.
Since its inception in 2002, Chromocell Therapeutics Corporation has been committed to pioneering advancements in pain management through rigorous research and development efforts. With a focus on leveraging cutting-edge scientific insights and proprietary technologies, the company continues to push boundaries in the field of biotechnology, aiming to deliver transformative treatments that enhance the quality of life for patrients worldwide.